A group from Medical University of Białystok, Poland, etc. has reported about therapeutic effects of Tocilizumab on COVID-19.
https://www.mdpi.com/2077-0383/10/8/1583/htm
In this clinical study with total 825 patients, Tocilizumab was administered to 170 patients and nothing was administered to 655 patients not only Tocilizumab but also any mAbs for cytokine receptors. The dose of Tocilizumab was 8mg/kg (the maximum dose =800mg) in a single dose.
In case of IL-6>100pg/mL, significant therapeutic effect of Tocilizumab was obtained (hazard ratio [HR]=0.21（95% confidence interval [CI]: 0.08–0.57). When IL-6>100pg/mL and either oxygen saturation <90% or requiring oxygen supplementation, HR decreased to 0.18. In addition, it was concluded that Tocilizumab has little therapeutic effect when IL-6<100pg/mL.
Anyhow, it is so great to know that Tocilizumab shows its therapeutic effect on what levels of serum IL-6 and how much dose is required for that.
